Companies/Heron Therapeutics, Inc.

Company profile

Heron Therapeutics, Inc.

NASDAQ: HRTX · Healthcare · Biotechnology

PublicHQ Cary, CACIK 0000818033Reports USD

#305 of 1,394 Healthcare companies by revenue52nd-percentile growth

EA Score

58C

FH 51DQ 60GM 66SS 74

v0.1 · 65/100 weight · provisional

↑ listing tenure, growth stability · ↓ return on equity, balance-sheet leverage

Methodology →

Revenue TTM

$150.7M

Rev growth YoY (TTM)

+1.5%

Net income (FY)

-$20.2M

Employees

122

Market cap

$69.2M

Financials — latest annual

SEC EDGAR · USD-normalized

ConceptUSDNativeFY

Revenue$154.9M$154.9M2025

Net income-$20.2M-$20.2M2025

Operating income-$2.5M-$2.5M2025

Total assets$255.9M$255.9M2025

Liabilities$241.5M$241.5M2025

Equity$14.3M$14.3M2025

Revenue trend

FY2020 – FY2025 · USD

$22.7M

FY20

$20.0M

FY20

$88.6M

FY20

$86.3M

FY21

$107.7M

FY22

$127.0M

FY23

$144.3M

FY24

$154.9M

FY25

Revenue by segment

Filed disclosures · FY2025

By product

C I N V A N T I68%

Z Y N R E L E F27%

S U S T O L6%

By geography

Not disclosed.

The read

Heron Therapeutics, Inc. booked $154.9M in FY2025 revenue, growing 7.4% year over year — about the middle of the pack among Healthcare companies we track, at a -13.0% net margin.

Peers · Healthcare

XBiotech Inc.47D MediciNova, Inc.43D Nakamoto Inc.31D NRx Pharmaceuticals, Inc.23D

Key facts

CEOCraig Alexander Collard

SectorHealthcare

IndustryBiotechnology

HeadquartersCary, CA

ExchangeNASDAQ: HRTX

Employees122

IPO date1987-08-26

Latest filings

8-K2026-06-25 8-K2026-06-16 8-K2026-06-02 10-Q2026-05-11 8-K2026-05-11 DEF 14A2026-04-30 8-K2026-04-06 10-K2026-02-26

Financials: SEC EDGAR (XBRL), USD-normalized per IAS 21 · TTM/quarterly + segments: FMP from filed disclosures · Filings: EDGAR submissions. County headcount and EA Score are in progress — see docs/DATA_GAPS.md.